Ensuring early access to a COVID-19 vaccine in Canada.

Download Full Article Article Brief


Brett J Skinner, PhD  

Canadian Health Policy, October 2020. ISSN 2562-9492 www.canadianhealthpolicy.com


Given the huge demand for a COVID-19 vaccine, there is a serious potential for shortages and international queuing. The World Health Organization is concerned that there will not be equitable access across developed and developing countries. This paper argues that, even developed countries risk being deprioritized in the queue for access to a new COVID-19 vaccine if they have small markets, onerous regulatory and health technology assessment processes, restrictive pricing policies and funding mechanisms, or policies that jeopardize the intellectual property rights of vaccine makers. Canada is particularly vulnerable because it represents a small percentage of the global vaccines market and its processes and policies are a potential barrier to early access to a COVID-19 vaccine.  


Founder and CEO, Canadian Health Policy Institute. Editor, Canadian Health Policy.  


August 26, 2020


October 13, 2020


This study was funded by an independent research grant from Pfizer Canada Inc.

©Canadian Health Policy Institute Inc. All rights reserved. Unauthorized reproduction or distribution of this article in whole or in part is strictly prohibited. 


1. CIRID (2020). Submission to the PMPRB Draft Guidelines Consultation. Centre for Immunization and Respiratory Infectious Diseases, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada. 13 February 2020.

2. FDA (2019). FY 2019 Performance Report to Congress for the Prescription Drug User Fee Act. US Food and Drug Administration.  

3. Ferguson, Neil M et al (2020). Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team. WHO Collaborating Centre for Infectious Disease Modelling, Imperial College London. 16 March 2020. 

4. Gouglas, D et al (2018). Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health 2018; 6: e1386–96. October 17, 2018.

5. Health Canada (2020). Biologic and Radiopharmaceutical Drugs Directorate Drug Submission Performance Annual Report Fiscal Year 2019-2020. April 1 2019 – March 31 2020.

6. HHS (2020). Fact Sheet: Explaining Operation Warp Speed. US Department of Health and Human Services.  

7. JHU (2020). Johns Hopkins University, Coronavirus Resource Center.   

8. NZ MOH (2020). COVID-19 Vaccine Strategy. New Zealand, Ministry of Health.  

9. ON AG (2014). 2014 Annual Report of the Office of the Auditor General of Ontario.

10. PBO (2020). Scenario Analysis Update: COVID-19 Pandemic and Oil Price Shocks, June 18, 2020; and Provincial Government Liquidity Outlook, 25 June 2020. Parliamentary Budget Officer.

11. PM AUS (2020). Media release: New deal secures potential COVID-19 vaccine for every Australian. August 19, 2020. Prime Minister, Minister for Health, Minister for Industry Science and Technology.     

12. Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME (2013). Risk in Vaccine Research and Development Quantified. PLoS ONE 8(3): e57755. 

13. Rawson, Nigel SB; Lawrence, Donna (2020). New Patented Medicine Regulations in Canada: Updated Case Study of a Manufacturer’s Decision-Making about a Regulatory Submission for a Rare Disorder Treatment. Canadian Health Policy, January 2020. 

14. Rechel, Bernd et al (2018). The organization and delivery of vaccination services in the European Union. European Observatory on Health Systems and Policies.

15. Skinner, Brett J (2018). Consequences of over-regulating the prices of new drugs in Canada. Canadian Health Policy, March 27, 2018.  

16. Skinner, Brett J (2020). COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada. Canadian Health Policy, June 2020.

17. The College of Physicians of Philadelphia (2020).

18. UK Government (2020). Press release: UK government secures new COVID-19 vaccines and backs global clinical trial. Published 14 August 2020. Department for Business, Energy & Industrial.

19. (VC 2020). Vaccines Industry Committee, submission to the PMPRB draft guidelines consultation. August 4, 2020. 

20. WHO (2020). 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility. 24 August 2020 News release.

Subscribe image

CHP blogazine